{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:14:27Z","timestamp":1778836467614,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015725","name":"Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy","doi-asserted-by":"publisher","award":["1U01 CA180964"],"award-info":[{"award-number":["1U01 CA180964"]}],"id":[{"id":"10.13039\/100015725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009786","name":"Hall Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009786","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["ACS-IRG-16-194-07"],"award-info":[{"award-number":["ACS-IRG-16-194-07"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UL1 TR000001"],"award-info":[{"award-number":["UL1 TR000001"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA242845-01A1"],"award-info":[{"award-number":["1R01CA242845-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UL1 TR000371"],"award-info":[{"award-number":["UL1 TR000371"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003389","name":"Fresenius Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003389","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013899","name":"FUJIFILM Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013700","name":"National Comprehensive Cancer Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP1100584"],"award-info":[{"award-number":["RP1100584"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001767","name":"National Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.esmoop.2021.100172","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T03:51:55Z","timestamp":1625629915000},"page":"100172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma"],"prefix":"10.1016","volume":"6","author":[{"given":"V.","family":"Subbiah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kuravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.R.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.J.","family":"Vivian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.U.","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Behrang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.W.","family":"Madison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Venstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.A.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.M.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Balusu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100172_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.critrevonc.2012.02.005","article-title":"Anaplastic large cell lymphoma, ALK-positive","volume":"83","author":"Ferreri","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2021.100172_bib2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11899-018-0436-z","article-title":"Update on the treatment of anaplastic large cell lymphoma","volume":"13","author":"Vu","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.esmoop.2021.100172_bib3","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1182\/blood-2007-04-060715","article-title":"Pathobiology of ALK+ anaplastic large-cell lymphoma","volume":"110","author":"Amin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2021.100172_bib4","doi-asserted-by":"crossref","first-page":"a001115","DOI":"10.1101\/mcs.a001115","article-title":"ALK: a tyrosine kinase target for cancer therapy","volume":"3","author":"Holla","year":"2017","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"10.1016\/j.esmoop.2021.100172_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2021.100172_bib6","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.esmoop.2021.100172_bib7","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-mutated acute myeloid leukemia: from bench to bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2021.100172_bib8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.blre.2017.11.001","article-title":"When the good go bad: mutant NPM1 in acute myeloid leukemia","volume":"32","author":"Kunchala","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.esmoop.2021.100172_bib9","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.18632\/oncotarget.2170","article-title":"The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in\u00a0vitro and in a systemic xenograft lymphoma model","volume":"5","author":"George","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2021.100172_bib10","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1128\/MCB.17.4.2312","article-title":"Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis","volume":"17","author":"Bischof","year":"1997","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.esmoop.2021.100172_bib11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1158\/2159-8290.CD-12-0009","article-title":"ALKoma: a cancer subtype with a shared target","volume":"2","author":"Mano","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2021.100172_bib12","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1158\/1078-0432.CCR-08-2762","article-title":"Inhibition of ALK signaling for cancer therapy","volume":"15","author":"Mosse","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100172_bib13","first-page":"3692","article-title":"Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma","volume":"9","author":"Khoury","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100172_bib14","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood.V96.13.4319","article-title":"Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase\/Akt antiapoptotic signaling pathway","volume":"96","author":"Bai","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2021.100172_bib15","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1038\/sj.onc.1207703","article-title":"Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma","volume":"23","author":"Amin","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.esmoop.2021.100172_bib16","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14740","article-title":"The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: a Nordic Lymphoma Group study","volume":"178","author":"Cederleuf","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.esmoop.2021.100172_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2021.100172_bib18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/annonc\/mdg070","article-title":"Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma","volume":"14","author":"Limat","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100172_bib19","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100172_bib20","first-page":"45","article-title":"Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin","volume":"7","author":"Chen","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.esmoop.2021.100172_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-016-0267-0","article-title":"Therapeutic options in peripheral T cell lymphoma","volume":"9","author":"Zhang","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.esmoop.2021.100172_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41698-018-0055-0","article-title":"Recent advances in precision oncology research","volume":"2","author":"Bode","year":"2018","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.esmoop.2021.100172_bib23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2005-05-2125","article-title":"Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas","volume":"107","author":"Piva","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2021.100172_bib24","doi-asserted-by":"crossref","first-page":"120ra117","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.esmoop.2021.100172_bib25","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100172_bib26","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100172_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1586\/14737140.2016.1131612","article-title":"Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib","volume":"16","author":"Muller","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.esmoop.2021.100172_bib28","first-page":"639","article-title":"Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers","volume":"4","author":"Chuang","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100172_bib29","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.2147\/DDDT.S113500","article-title":"Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy","volume":"11","author":"Santarpia","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.esmoop.2021.100172_bib30","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/jm400402q","volume":"56","author":"Marsilje","year":"2013","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.esmoop.2021.100172_bib31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100172_bib32","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0002-9440(10)64248-4","article-title":"The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas","volume":"161","author":"Raetz","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.esmoop.2021.100172_bib33","doi-asserted-by":"crossref","first-page":"9002","DOI":"10.1158\/0008-5472.CAN-05-4101","article-title":"The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner","volume":"66","author":"Hsu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100172_bib34","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1073\/pnas.0500187102","article-title":"TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2\/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs","volume":"102","author":"Hauer","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.esmoop.2021.100172_bib35","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2006-07-025809","article-title":"Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications","volume":"109","author":"Jost","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2021.100172_bib36","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2021.100172_bib37","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1634\/theoncologist.2016-0488","article-title":"ALK fusions in a wide variety of tumor types respond to anti-ALK targeted therapy","volume":"22","author":"Ross","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2021.100172_bib38","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1074\/mcp.O116.059253","article-title":"Omics profiling in precision oncology","volume":"15","author":"Yu","year":"2016","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.esmoop.2021.100172_bib39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100172_bib40","first-page":"429","article-title":"ALK inhibitors in non-small cell lung cancer: crizotinib and beyond","volume":"12","author":"Awad","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.esmoop.2021.100172_bib41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1158\/1535-7163.MCT-10-0615","article-title":"Targeting oncogenic ALK: a promising strategy for cancer treatment","volume":"10","author":"Grande","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.esmoop.2021.100172_bib42","first-page":"1657","article-title":"IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma","volume":"136","author":"Prokoph","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2021.100172_bib43","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/1541-7786.MCR-12-0569","article-title":"Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors","volume":"11","author":"Ceccon","year":"2013","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100172_bib44","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1182\/blood-2014-12-617779","article-title":"Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma","volume":"126","author":"Richly","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2021.100172_bib45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fonc.2012.00041","article-title":"ALK signaling and target\u00a0therapy in anaplastic large cell lymphoma","volume":"2","author":"Tabbo","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2021.100172_bib46","doi-asserted-by":"crossref","first-page":"9699","DOI":"10.1073\/pnas.93.18.9699","article-title":"CD30\/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity","volume":"93","author":"Lee","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.esmoop.2021.100172_bib47","doi-asserted-by":"crossref","first-page":"10252","DOI":"10.1074\/jbc.M608817200","article-title":"CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells","volume":"282","author":"Wright","year":"2007","journal-title":"J\u00a0Biol Chem"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:47:42Z","timestamp":1778834862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921001320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S2059702921001320"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100172","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100172"}}